Cotrimoxazole for infection prevention in glomerulonephritis treated with rituximab: a randomized controlled trial.

ABSTRACT:

Objectives

We aimed to evaluate the safety and efficacy of cotrimoxazole for preventing infections in patients with glomerulonephritis (GN) receiving rituximab (RTX) therapy.

Study design and methods

This single-center, open-label randomized controlled trial enrolled 150 patients with GN who received RTX at Xijing Hospital between October 2022 and December 2023. Participants were randomized 1:1 to either the cotrimoxazole prophylaxis group (n = 75) or the non-cotrimoxazole group (n = 75). The primary endpoint was the cumulative incidence of infection over a 180-day follow-up period. Secondary endpoints included the incidence of severe infections and the rate of adverse events (AEs) attributed to cotrimoxazole.

Intervention

All patients received RTX at a dose of 1000 m

SUBMITTER: Chen Y 

PROVIDER: S-EPMC12723918 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature